ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Rejects Petition to Ban Pfizer Inc. (PFE) Alzheimer Pill


11/7/2012 7:23:17 AM

The bitter wrangling between the FDA and Public Citizen over the Aricept pill for Alzheimer’s continues. Yesterday, the agency informed the watchdog that its petition seeking a ban on the highest dose was rejected, two months after Public Citizen sued the FDA for not responding to its petition (here is the lawsuit). Public Citizen sought the ban on the 23mg due to high rates of toxicity and also wanted the agency to warn doctors and patients against the 20mg – or combining the 5mg and 10mg pills – for similar reasons. Aricept, which is marketed by Pfizer and Eisai, was approved for patients with moderate to severe Alzheimer’s. As we noted previously, the petition argued that the only clinical trial submitted to the FDA for approval of the 23mg dose compared it to the 10mg dose, but failed to prove the higher dose was more effective. And in three of four tests, there was no significant difference between the doses on a cognitive or functional level.

Read at Pharmalot


 Read Article at  Related Companies  News Categories
Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES